|
WO2020201078A1
|
|
Prescription of remote patient management based on biomarkers
|
|
WO2020169819A1
|
|
Diagnosis or prognosis of postsurgical adverse events
|
|
WO2020169799A1
|
|
Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
|
|
WO2020156988A1
|
|
Method to predict treatment response in patients with nocturnal enuresis
|
|
EP3763443A1
|
|
Multiple magazine for caps of a poc test system
|
|
EP3803396A1
|
|
Biomarkers for the diagnosis of invasive fungal infections
|
|
EP3715851A1
|
|
Prescription of remote patient management based on biomarkers
|
|
EP3699596A1
|
|
Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
|
|
EP3729083A1
|
|
Antibiotic therapy guidance based on pro-adm
|
|
CN111656189A
|
|
Antibiotic therapy guidance based on procalcitonin in patients with complications
|
|
EP3608673A1
|
|
Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
|
|
WO2019053118A1
|
|
Proadrenomedullin as a marker for abnormal platelet levels
|
|
US2020264199A1
|
|
Pct and pro-adm as markers for monitoring antibiotic treatment
|
|
CA3075440A1
|
|
Pro-adm as a therapy monitoring marker for critcally ill patients
|
|
EP3682236A1
|
|
Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
|
|
EP3578989A1
|
|
Pro-adm for prognosis of trauma-related complications in polytrauma patients
|
|
EP3631460A1
|
|
Mmp-8 as a marker for identifying infectious disease
|
|
US2020081018A1
|
|
Proadm and/or histones as markers indicating an adverse event
|
|
EP3502691A1
|
|
Proadrenomedullin as indicator for renal replacement therapy in critically ill patients
|
|
EP3502706A1
|
|
Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
|
